These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 26729183)

  • 21. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
    Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
    Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies - A new era in the treatment of multiple myeloma.
    Jelinek T; Hajek R
    Blood Rev; 2016 Mar; 30(2):101-10. PubMed ID: 26362528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Blair HA
    Drugs; 2017 Dec; 77(18):2013-2024. PubMed ID: 29127588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
    Jing H; Yang L; Qi J; Qiu L; Fu C; Li J; Yang M; Qi M; Fan N; Ji J; Lu J; Li Y; Jin J
    Ann Hematol; 2022 Dec; 101(12):2679-2690. PubMed ID: 36301338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.
    Kumar S; Durie B; Nahi H; Vij R; Dimopoulos MA; Kastritis E; Terpos E; Leleu X; Beksac M; Goldschmidt H; Hillengass J; Su Z; Hutton B; Cameron C; Khan I; Lam A
    Leuk Lymphoma; 2019 Jan; 60(1):163-171. PubMed ID: 29741423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teclistamab: First Approval.
    Kang C
    Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daratumumab for the Treatment of Multiple Myeloma.
    Plesner T; Krejcik J
    Front Immunol; 2018; 9():1228. PubMed ID: 29915586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.
    Hofmeister CC; Lonial S
    J Clin Oncol; 2016 Dec; 34(36):4421-4430. PubMed ID: 27998219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daratumumab for the treatment of multiple myeloma.
    Goldsmith SR; Foley N; Schroeder MA
    Drugs Today (Barc); 2021 Oct; 57(10):591-605. PubMed ID: 34713868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
    Clemens PL; Yan X; Lokhorst HM; Lonial S; Losic N; Khan I; Jansson R; Ahmadi T; Lantz K; Zhou H; Puchalski T; Xu XS
    Clin Pharmacokinet; 2017 Aug; 56(8):915-924. PubMed ID: 27896689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.
    Byun JM; Yoon SS; Koh Y; Kim I; Jo J; Park H; Lee JO; Lee J
    Anticancer Res; 2019 Sep; 39(9):5165-5170. PubMed ID: 31519629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isatuximab: First Approval.
    Dhillon S
    Drugs; 2020 Jun; 80(9):905-912. PubMed ID: 32347476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.
    Cao C; Zhou X; Ma Q
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00797. PubMed ID: 34128350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
    Kim K; Phelps MA
    Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
    Laubach JP; Paba Prada CE; Richardson PG; Longo DL
    Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
    Paul B; Atrash S; Bhutani M; Voorhees P; Hamadeh I; Usmani SZ
    Expert Rev Hematol; 2020 Aug; 13(8):795-802. PubMed ID: 32659139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
    Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort.
    Maouche N; Srinivasan A; Leary H; Collings F; Tseu B; Vallance GD; Ramasamy K; Kothari J
    J Oncol Pharm Pract; 2023 Mar; 29(2):299-304. PubMed ID: 34939868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.